Bemcentinib

Phase 3Small molecule

BBerGenBio ASA

Bemcentinib is one of 216 small molecule programs targeting Lung Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

215

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

COVID-19Active, not recruiting

Lung AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Active, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Bemcentinib

BBerGenBio ASA

Phase 3

1 2

Aldactone

Pfizer

Preclinical

1 3

Nexavar

Bayer

Preclinical

1 4

Rayaldee

OOrganon and Co

Preclinical

1 5

Tricor

JJagotec

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Benadryl

PParkedale

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Selenium

SSWOG Cancer Research Network

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Lung Adenocarcinoma

NCT06516887

Q1 2031

Phase 3Not yet recruiting

Head and Neck Squamous Cell Carcinoma

NCT07445048

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Completed·BBerGenBio ASA·Phase 1/2·NCT02424617·40 enrolled

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Completed·BBerGenBio ASA·Phase 2·NCT03184571·99 enrolled

A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

Terminated·BBerGenBio ASA·Phase 1/2·NCT05469178·26 enrolled

Pancreatic Cancer1 trial

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT03649321·9 enrolled

Myelodysplastic Syndromes1 trial

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

Completed·GGWT-TUD GmbH·Phase 2·NCT03824080·45 enrolled

Lung Adenocarcinoma1 trial

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT06516887·44 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 3·NCT07445048·370 enrolled

3 more indications

COVID-191 trial

A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

Completed·BBerGenBio ASA·Phase 2·NCT04890509·115 enrolled

Phase IB1 trial

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Completed·BBerGenBio ASA·Phase 1/2·NCT02488408·122 enrolled

Unspecified1 trial

A Study to Investigate 14C-bemcentinib in Healthy Male Subjects

Completed·BBerGenBio ASA·Phase 1·NCT06469138·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Bemcentinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bemcentinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bemcentinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BerGenBio ASA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBerGenBio ASA

Bemcentinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2031

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Pancreatic Cancer1 trial

Myelodysplastic Syndromes1 trial

Lung Adenocarcinoma1 trial

Head and Neck Squamous Cell Carcinoma1 trial

COVID-191 trial

Phase IB1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News